Tirzepatide (Mounjaro) Reduces Alcohol Intake & Relapse in Animal Study

A medication already approved for type 2 diabetes and weight loss shows promising potential in addressing alcohol use disorder. Researchers have discovered that tirzepatide – the active ingredient in the drug Mounjaro – significantly reduces alcohol intake and relapse-like behaviors in rodent models.

The findings, published in February 2026 in the journal eBioMedicine, build upon previous research demonstrating the effectiveness of semaglutide – found in Ozempic and Wegovy – in curbing alcohol consumption in rats. This new study shifts the focus to tirzepatide, offering further insight into the potential of this class of drugs for treating alcohol use disorder.

In the study, voluntary alcohol consumption decreased by more than 50% in animals treated with tirzepatide. Importantly, the drug also prevented relapse-like drinking patterns. After a period of abstinence, the animals did not exhibit the typical increase in alcohol consumption often seen in relapse models; instead, their intake remained lower than previous levels.

We observed clear and robust reductions in long-term alcohol consumption, binge-like drinking, and relapse-like drinking in both male and female animals. What makes this study particularly compelling is that it also provides new insight into how this class of drugs may influence the brain’s reward system.

Christian Edvardsson, doctoral student in pharmacology, Sahlgrenska Academy, University of Gothenburg

How Tirzepatide Impacts Alcohol-Related Behaviors

Tirzepatide is unique as the first medication to function as a dual agonist, activating receptors for both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), hormones that regulate satiety. Its established safety profile, due to its widespread use in treating type 2 diabetes, could expedite future research into its application for alcohol use disorder.

The researchers found that tirzepatide dampened the effects of alcohol on dopamine, a crucial neurotransmitter within the brain’s reward system that contributes to alcohol’s reinforcing properties. This effect appears to be mediated, at least in part, through activity in the lateral septum, a brain region known to be involved in motivation, reward processing, and relapse vulnerability in both animal models and humans. These findings offer a potential neurological explanation for previous observations suggesting that similar medications can reduce alcohol consumption and cravings.

Further molecular analysis revealed changes in histone-related proteins within the lateral septum. These proteins play a role in regulating gene expression, essentially controlling which genes are “switched on” or “off.” Alterations in these proteins have been previously linked to substance use and addiction. However, the study authors emphasize that these changes do not necessarily *cause* the reduction in alcohol consumption, but rather may represent part of the complex biological mechanisms influenced by tirzepatide.

Future Directions and Considerations

This research was a collaborative effort between researchers at the University of Gothenburg and colleagues at the Medical University of South Carolina. The study combined behavioral tests assessing alcohol intake with measurements of neurotransmitter levels in the brain and detailed molecular analyses.

“This is not yet a new treatment for alcohol use disorder,” explains Elisabet Jerlhag Holm, Professor of Pharmacology at the Sahlgrenska Academy, University of Gothenburg. “But the findings reinforce the view that drugs targeting these neural systems may be relevant to investigate further as potential treatment options.”

While these findings are encouraging, it’s important to note that this research was conducted on animal models. Further studies are needed to determine whether tirzepatide will have similar effects in humans with alcohol use disorder. Clinical trials would be necessary to assess the drug’s safety and efficacy in a human population, as well as to determine optimal dosages and potential side effects.

Alcohol use disorder is a complex condition with a variety of contributing factors, including genetic predisposition, environmental influences, and psychological factors. Tirzepatide, if proven effective in humans, would likely be used as part of a comprehensive treatment plan that includes behavioral therapies, counseling, and support groups.

The ongoing research into medications like tirzepatide and semaglutide offers a new avenue for addressing this significant public health challenge, providing hope for the development of more effective treatments for individuals struggling with alcohol use disorder.